Atara Biotherapeutics - ATRA Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings or view top-rated stocks.

7 brokerages have issued 12 month price objectives for Atara Biotherapeutics' shares. Their ATRA share price forecasts range from $3.00 to $50.00. On average, they predict the company's share price to reach $19.25 in the next twelve months. This suggests a possible upside of 587.5% from the stock's current price.
View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts.

Atara Biotherapeutics' stock was trading at $3.28 at the start of the year. Since then, ATRA stock has decreased by 14.6% and is now trading at $2.80.
View the best growth stocks for 2023 here.

Atara Biotherapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 16,700,000 shares, an increase of 18.7% from the February 28th total of 14,070,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 13.1 days.
View Atara Biotherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ATRA earnings forecast.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings data on Wednesday, February, 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.11. The biotechnology company earned $0.22 million during the quarter, compared to analyst estimates of $60 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 140.05% and a negative net margin of 359.12%.

ETFs with the largest weight of Atara Biotherapeutics (NASDAQ:ATRA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and iShares Biotechnology ETF (IBB).

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (7.82%), Maverick Capital Ltd. (6.56%), Morgan Stanley (2.80%), Geode Capital Management LLC (1.92%), Citigroup Inc. (1.08%) and Dimensional Fund Advisors LP (0.94%). Insiders that own company stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends.

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRA stock can currently be purchased for approximately $2.80.

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $268.60 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

The company employs 578 workers across the globe.

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com.